In addition to lowering blood pressure, treatments for pulmonary arterial hypertension (PAH) probably work at least in part by preventing physical changes in the architecture of the lung’s blood vessels that are associated with the progression of the disease, according to a study. “Our findings suggest that the beneficial…
People with pulmonary hypertension are at increased risk of developing cancer, especially lung and skin cancers, a new study indicates. The study, “Pulmonary hypertension is associated with an increased incidence of cancer diagnoses,” was published in the journal Pulmonary Circulation. Pulmonary hypertension (PH) refers to…
Tenax Therapeutics has completed a pharmacological assessment of TNX-201, the company’s new oral formulation of imatinib for pulmonary arterial hypertension (PAH), in healthy volunteers. The assessment included comparisons against Gleevec, another oral formulation of imatinib sold by Novartis that is approved to treat certain blood cancers, but was…
Pulmonary Hypertension News brought you the latest coverage of advances in treatment, clinical trials, and scientific research related to pulmonary hypertension (PH) throughout 2021. We look forward to continuing to report more news to patients, family members, and caregivers dealing with PH in the new year. Here are the…
Care at a specialty center is tied to a lower risk of hospitalization for people with heart failure with preserved ejection fraction (HFpEF) who have pulmonary hypertension, according to a new study. The study, “Improved Hospitalization Rates in a Specialty Center for Heart Failure with Preserved Ejection Fraction…
Children with pulmonary arterial hypertension (PAH) report poorer health-related quality of life (HRQoL) than their peers, a study shows. Results also suggest that worse HRQoL in children with PAH is linked with more severe depression in their parents, which suggests that providing support to families may help to improve…
Aerovate Therapeutics is starting a Phase 2b/3 clinical trial that will test AV-101, the company’s experimental inhaled formulation of imatinib, in people with pulmonary arterial hypertension (PAH). “We are excited and humbled to initiate this Phase 2b/Phase 3 trial of AV-101. Starting enrollment represents an important milestone for Aerovate Therapeutics and…
Beyond Air has announced that it is not expecting the U.S. Food and Drug Administration (FDA) to approve its LungFit PH device to treat persistent pulmonary hypertension of the newborn (PPHN) before the end of the year. Beyond Air filed an application with the FDA in late…
Treatment with the experimental medication KER-012 helped to prevent heart damage in a mouse model of pulmonary hypertension, new research shows. The findings were showcased by KER-012’s developer, Keros Therapeutics, at the American Heart Association (AHA) 2021 Scientific Sessions, held Nov. 13–15, according to a company press…
By analyzing how medications affect the genetic activity of cells, researchers developed a computational pipeline that may be useful in repurposing cancer treatments for use in other diseases. Leveraging this pipeline, the team identified two compounds, I-BET762 and BRD2889, that might be refined — more quickly and at lower cost…
Due to problems at a third-party facility, the U.S. Food and Drug Administration (FDA) has decided to not approve Tyvaso DPI, a dry powder inhaled formulation of treprostinil, at this time. According to United Therapeutics, the medication’s developer, the issue is expected to be dealt with soon. The company anticipates…
People with pulmonary hypertension (PH) who start treatment with opioids to manage pain after undergoing surgery are at high risk of continuing to take these addictive medications for longer than required, new research suggests. Indeed, hypertension was one of eight specifically identified “top risk factors” for “new persistent post-surgical…
Get regular updates to your inbox.